📣 VC round data is live. Check it out!

Daxor Valuation Multiples

Discover revenue and EBITDA valuation multiples for Daxor and similar public comparables like Pentixapharm Holding, Sensus Healthcare, Tobii, HeartBeam and more.

Daxor Overview

About Daxor

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.


Founded

1971

HQ

United States

Employees

12

Website

daxor.com

Financials (LTM)

Revenue: $9M
Net Income: ($633K)

EV

$61M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Daxor Financials

Daxor reported last 12-month revenue of $9M.

In the same LTM period, Daxor generated $6M in gross profit and had net loss of ($633K).

Revenue (LTM)


Daxor P&L

In the most recent fiscal year, Daxor reported revenue of $10M and net income of $9M.

Daxor is profitable as of last fiscal year, with net margin of 89%.

See analyst estimates for Daxor
LTMLast FY202320242025202620272028
Revenue$9M$10M$1M$2M$10M
Gross Profit$6M$8M
Gross Margin71%81%
EBIT Margin(7%)(3%)(3%)
Net Profit($633K)$9M$281K$536K$9M
Net Margin(7%)89%22%25%89%

Financial data powered by Morningstar, Inc.

Daxor Stock Performance

Daxor has current market cap of $61M, and enterprise value of $61M.

Market Cap Evolution


Daxor's stock price is $10.50.

Daxor share price decreased by 2.8% in the last 30 days, and increased by 29.7% in the last year.

Daxor has an EPS (earnings per share) of $1.57.

See more trading valuation data for Daxor
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$61M$61M0.0%-2.8%-11.5%29.7%$1.57

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Daxor Valuation Multiples

Daxor trades at 7.1x EV/Revenue multiple.

See NTM and 2027E valuation multiples for Daxor

EV / Revenue (LTM)


Daxor Financial Valuation Multiples

As of May 15, 2026, Daxor has market cap of $61M and EV of $61M.

Daxor has a P/E ratio of (96.7x).

LTMLast FY202320242025202620272028
EV/Revenue7.1x5.9x47.8x28.7x5.9x
EV/EBIT(96.7x)(204.0x)(204.0x)
EV/Gross Profit10.0x7.4x
P/E(96.7x)6.7x218.0x114.1x6.7x
EV/FCF107.2x(16.7x)n/m107.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Daxor Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Daxor Margins & Growth Rates

Daxor grew revenue by 15% but net profit decreased by 113% in the last fiscal year.

In the most recent fiscal year, Daxor reported net margin of 89%.

See estimated margins and future growth rates for Daxor

Daxor Margins

Last FY202420252026202720282029
Gross Margin81%71%
EBIT Margin(3%)(3%)(10%)
Net Margin89%25%89%(10%)
FCF Margin6%1%6%

Daxor Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth15%66%384%15%
Gross Profit Growth2%
EBIT Growth300%300%
Net Profit Growth(113%)91%1610%(113%)
FCF Growth(101%)2122%

Data powered by FactSet, Inc. and Morningstar, Inc.

Daxor Operational KPIs

Daxor's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Daxor
LTMLast FY202320242025202620272028
Revenue per Employee$0.9M
Opex per Employee$0.1M
G&A Expenses to Revenue3%24%14%3%
R&D Expenses to Revenue14%10%10%
Opex to Revenue11%78%75%11%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Pentixapharm Holding503.6x(3.0x)
Sensus Healthcare1.5x1.6x(4.3x)(4.5x)
Tobii1.2x1.3x3.4x4.3x
HeartBeam73.1x(2.6x)
Pangaea Oncology4.0x(61.4x)
SMAIO5.2x4.7x(54.0x)(54.5x)
BATM Advanced Communications0.4x0.5x2.7x3.9x
Pulmonx0.6x0.6x(1.5x)(1.6x)

This data is available for Pro users. Sign up to see all Daxor competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Daxor

When was Daxor founded?Daxor was founded in 1971.
Where is Daxor headquartered?Daxor is headquartered in United States.
How many employees does Daxor have?As of today, Daxor has over 12 employees.
Who is the CEO of Daxor?Daxor's CEO is Michael R. Feldschuh.
Is Daxor publicly listed?Yes, Daxor is a public company listed on Nasdaq.
What is the stock symbol of Daxor?Daxor trades under DXR ticker.
When did Daxor go public?Daxor went public in 1983.
Who are competitors of Daxor?Daxor main competitors include Pentixapharm Holding, Sensus Healthcare, Tobii, HeartBeam, Pangaea Oncology, SMAIO, BATM Advanced Communications, Pulmonx, Gentian Diagnostics, Xtant Medical.
What is the current market cap of Daxor?Daxor's current market cap is $61M.
What is the current revenue of Daxor?Daxor's last 12 months revenue is $9M.
What is the current revenue growth of Daxor?Daxor revenue growth (NTM/LTM) is 76%.
What is the current EV/Revenue multiple of Daxor?Current revenue multiple of Daxor is 7.1x.
Is Daxor profitable?No, Daxor is not profitable.
What is the current net income of Daxor?Daxor's last 12 months net income is ($633K).
How many companies Daxor has acquired to date?Daxor hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Daxor has invested to date?Daxor hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Daxor

Lists including Daxor

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial